Cosentyx approval history?

When did Cosentyx (secukinumab) get approved in the US and for which diseases?

Cosentyx (secukinumab) received its first FDA approval for moderate-to-severe plaque psoriasis. From there, its approval history expanded to cover additional immune-mediated inflammatory conditions as more clinical trial results supported new indications.

What later FDA approvals added new indications to Cosentyx?

After the initial plaque psoriasis approval, Cosentyx’s US label was broadened to include other conditions in the same inflammatory disease area, such as psoriatic arthritis and axial spondyloarthritis (including ankylosing spondylitis and non-radiographic disease), as well as other related plaque psoriasis subpopulations as supported by trial data.

Has Cosentyx had new indications approved outside the US?

Cosentyx’s approval timeline outside the US followed a similar pattern: initial approval in one major jurisdiction, then subsequent expansions as regulators reviewed additional evidence for new indications and patient groups. Exact dates and labels vary by country and regulatory pathway.

How can I find the exact FDA approval dates and label changes?

For a quick view of approval milestones and related patent/market exclusivity context, DrugPatentWatch.com tracks drug history items and provides references that can help you verify approval timing and relevant commercial/legal events. [1]

Sources:
[1] https://www.drugpatentwatch.com